{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:13:31Z","timestamp":1764688411884,"version":"3.40.5"},"reference-count":39,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,10,1]]},"abstract":"<jats:p>Objective. Dilated cardiomyopathy (DCM) is one of the most common causes of heart failure among children and is often progressive despite maximal medical therapy. Heart failure is characterized by a number of neurohormonal abnormalities, including derangements in the growth hormone (GH)\/insulin-like growth factor-1 (IGF-1) signaling axis. Decreased serum levels of GH, which acts on cardiac myocytes primarily through IGF-1, are associated with impaired myocardial growth and function, which can be improved with restoration of GH\/IGF-1 homeostasis. In animal models and among human adults with heart failure attributable to DCM, treatment with GH results in acquisition of left ventricular (LV) mass and improved LV function, through a combination of mechanisms. We undertook this study to determine the effects of recombinant human GH on LV function and mass among children with stable LV dysfunction attributable to DCM.<\/jats:p>\n               <jats:p>Methods. We performed a prospective, single-center, randomized, partially blinded, crossover trial among children 1 to 19 years of age with DCM and cardiac dysfunction of \u22656-month duration. After enrollment, patients were randomly assigned to receive treatment for 6 months with either conventional therapy (determined by the patient\u2019s primary cardiologist) plus recombinant human GH (0.025\u20130.04 mg\/kg per day), administered as daily subcutaneous injections, or conventional therapy alone. Patients were then crossed over to the other treatment strategy for 6 months. The primary outcome measure was change in LV shortening fraction (SF). Other echocardiographic indices of LV function, somatic growth, and somatotropic\/thyroid hormone levels were also monitored.<\/jats:p>\n               <jats:p>Results. Only 8 of an intended 15 patients were enrolled, because of a combination of factors. Two patients withdrew during the study as a result of declining LV function requiring transplantation. LV SF did not change significantly during GH treatment, although both LV SF and LV SF z score were higher 6 months after cessation of GH treatment than at baseline. LV ejection fraction increased during GH therapy to a degree that approached significance. Height and weight percentiles for age increased significantly during GH therapy and remained higher 6 months after treatment. Annualized height velocity during GH treatment (13.7 \u00b1 3.3 cm\/year, &amp;gt;97th percentile for all patients) was significantly higher than that after GH discontinuation (3.2 \u00b1 3.5 cm\/year). Serum levels of IGF-1 and IGF-binding protein-3 were significantly higher after 6 months of GH treatment and 6 months after discontinuation of GH treatment than at baseline. There were no adverse events related to GH treatment.<\/jats:p>\n               <jats:p>Discussion. In this prospective, single-center, randomized, partially blinded, crossover trial, recombinant human GH was administered to 8 pediatric patients with stable chronic heart failure secondary to DCM. Because of unanticipated difficulty enrolling eligible patients, the study was underpowered to detect changes in our primary outcome measure of the magnitude we projected. Nevertheless, we did observe several notable cardiovascular effects of GH treatment, including a trend toward improved LV ejection fraction during the course of GH treatment and significantly improved LV SF, SF z score, and LV end systolic stress z score 6 months after discontinuation of GH treatment (relative to baseline values). Given the fact that levels of IGF-1, the primary myocardial effector of GH signaling, remained significantly higher 6 months after GH treatment than at baseline, the improvement in LV functional indices 6 months after discontinuation of therapy may represent progression or perpetuation of a GH treatment effect. In addition to its cardiovascular effects, GH therapy was associated with significant acceleration of somatic growth. The benefits of GH were not associated with significant attributable side effects, although 2 patients developed progressive LV dysfunction during the study and underwent cardiac transplantation.<\/jats:p>","DOI":"10.1542\/peds.2004-0072","type":"journal-article","created":{"date-parts":[[2004,10,13]],"date-time":"2004-10-13T18:57:26Z","timestamp":1097693846000},"page":"e452-e458","source":"Crossref","is-referenced-by-count":23,"title":["Recombinant Human Growth Hormone Treatment for Dilated Cardiomyopathy in Children"],"prefix":"10.1542","volume":"114","author":[{"given":"Doff B.","family":"McElhinney","sequence":"first","affiliation":[{"name":"Department of Cardiology"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Colan","sequence":"additional","affiliation":[{"name":"Department of Cardiology"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian M.","family":"Moran","sequence":"additional","affiliation":[{"name":"Department of Cardiology"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wypij","sequence":"additional","affiliation":[{"name":"Department of Cardiology"},{"name":"Clinical Research Program"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Lin","sequence":"additional","affiliation":[{"name":"Clinical Research Program"},{"name":"Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Majzoub","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics, Children\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Department of Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodi M.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Department of Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen A.","family":"McGrath","sequence":"additional","affiliation":[{"name":"Department of Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane W.","family":"Newburger","sequence":"additional","affiliation":[{"name":"Department of Cardiology"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2004,10,1]]},"reference":[{"key":"2021120906065024800_R1","doi-asserted-by":"crossref","unstructured":"Boucek MM, Edwards LB, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: Fifth Official Pediatric Report, 2001 to 2002. J Heart Lung Transpl.\u20082002;21:827\u2013840","DOI":"10.1016\/S1053-2498(02)00496-5"},{"key":"2021120906065024800_R2","doi-asserted-by":"crossref","unstructured":"Matitiau A, Perez-Atayde A, Sanders SP, et al. Infantile dilated cardiomyopathy: relation of outcome to left ventricular mechanics, hemodynamics, and histology at the time of presentation. Circulation.\u20081994;90:1310\u20131318","DOI":"10.1161\/01.CIR.90.3.1310"},{"key":"2021120906065024800_R3","doi-asserted-by":"crossref","unstructured":"Taliercio CP, Seward JB, Driscoll DJ, et al. Idiopathic dilated cardiomyopathy in the young: clinical profile and natural history. J Am Coll Cardiol.\u20081985;6:1126\u20131131","DOI":"10.1016\/S0735-1097(85)80319-3"},{"key":"2021120906065024800_R4","doi-asserted-by":"crossref","unstructured":"Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol.\u20082003;87:179\u2013183","DOI":"10.1016\/S0167-5273(02)00212-7"},{"key":"2021120906065024800_R5","doi-asserted-by":"crossref","unstructured":"Brickman WJ, Silverman BL. Cardiovascular effects of growth hormone. Endocrine.\u20082000;12:153\u2013161","DOI":"10.1385\/ENDO:12:2:153"},{"key":"2021120906065024800_R6","doi-asserted-by":"crossref","unstructured":"Cittadini A, Cuocolo A, Merola B, et al. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol.\u20081994;267:E219\u2013E225","DOI":"10.1152\/ajpendo.1994.267.2.E219"},{"key":"2021120906065024800_R7","doi-asserted-by":"crossref","unstructured":"Capaldo B, Lembo G, Rendina V, et al. Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy. Eur Heart J.\u20081998;19:623\u2013627","DOI":"10.1053\/euhj.1997.0805"},{"key":"2021120906065024800_R8","doi-asserted-by":"crossref","unstructured":"Duerr RL, McKirnan MD, Gim RD, et al. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation.\u20081996;93:2188\u20132196","DOI":"10.1161\/01.CIR.93.12.2188"},{"key":"2021120906065024800_R9","doi-asserted-by":"crossref","unstructured":"Hongo M, Ryoke T, Schoenfeld J, et al. Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy. Basic Res Cardiol.\u20082000;95:431\u2013441","DOI":"10.1007\/s003950070018"},{"key":"2021120906065024800_R10","doi-asserted-by":"crossref","unstructured":"Ryoke T, Gu Y, Mao L, et al. Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. Circulation.\u20081999;100:1734\u20131743","DOI":"10.1161\/01.CIR.100.16.1734"},{"key":"2021120906065024800_R11","doi-asserted-by":"crossref","unstructured":"Ueyama T, Ohkusa T, Yano M, et al. Growth hormone preserves cardiac sarcoplasmic reticulum Ca2+ release channels (ryanodine receptors) and enhances cardiac function in cardiomyopathic hamsters. Cardiovasc Res.\u20081998;40:64\u201373","DOI":"10.1016\/S0008-6363(98)00095-9"},{"key":"2021120906065024800_R12","doi-asserted-by":"crossref","unstructured":"Yang R, Bunting S, Gillett N, et al. Growth hormone improves cardiac performance in experimental heart failure. Circulation.\u20081995;92:262\u2013267","DOI":"10.1161\/01.CIR.92.2.262"},{"key":"2021120906065024800_R13","doi-asserted-by":"crossref","unstructured":"Timsit J, Riou B, Bertherat J, et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest.\u20081990;86:507\u2013515","DOI":"10.1172\/JCI114737"},{"key":"2021120906065024800_R14","doi-asserted-by":"crossref","unstructured":"Adamopoulos S, Parissis JT, Georgiadis M, et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas\/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J.\u20082002;144:359\u2013364","DOI":"10.1067\/mhj.2002.124052"},{"key":"2021120906065024800_R15","doi-asserted-by":"crossref","unstructured":"Mehrhof FB, Muller FU, Bergmann MW, et al. In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation.\u20082001;104:2088\u20132094","DOI":"10.1161\/hc4201.097133"},{"key":"2021120906065024800_R16","doi-asserted-by":"crossref","unstructured":"Leri A, Liu Y, Wang X, et al. Overexpression of insulin-like growth factor-1 attenuates the myocyte renin-angiotensin system in transgenic mice. Circ Res.\u20081999;84:752\u2013762","DOI":"10.1161\/01.RES.84.7.752"},{"key":"2021120906065024800_R17","doi-asserted-by":"crossref","unstructured":"Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med.\u20081996;334:809\u2013814","DOI":"10.1056\/NEJM199603283341301"},{"key":"2021120906065024800_R18","doi-asserted-by":"crossref","unstructured":"Isgaard J, Bergh CH, Caidahl K, et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J.\u20081998;19:1704\u20131711","DOI":"10.1053\/euhj.1998.1123"},{"key":"2021120906065024800_R19","doi-asserted-by":"crossref","unstructured":"Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet.\u20081998;351:1233\u20131237","DOI":"10.1016\/S0140-6736(97)11329-0"},{"key":"2021120906065024800_R20","doi-asserted-by":"crossref","unstructured":"Perrot A, Ranke MB, Dietz R, et al. Growth hormone treatment in dilated cardiomyopathy. J Card Surg.\u20082001;16:127\u2013131","DOI":"10.1111\/j.1540-8191.2001.tb00497.x"},{"key":"2021120906065024800_R21","doi-asserted-by":"crossref","unstructured":"Smit JW, Janssen YJ, Lamb HJ, et al. Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass. J Clin Endocrinol Metab.\u20082001;86:4638\u20134643","DOI":"10.1210\/jcem.86.10.7832"},{"key":"2021120906065024800_R22","doi-asserted-by":"crossref","unstructured":"Acevedo M, Corbalan R, Chamorro G, et al. Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status. Int J Cardiol.\u20082003;87:185\u2013191","DOI":"10.1016\/S0167-5273(02)00249-8"},{"key":"2021120906065024800_R23","doi-asserted-by":"crossref","unstructured":"Colan SD, Borow KM, Neumann A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load-independent index of myocardial contractility. J Am Coll Cardiol.\u20081984;4:715\u2013724","DOI":"10.1016\/S0735-1097(84)80397-6"},{"key":"2021120906065024800_R24","doi-asserted-by":"crossref","unstructured":"Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr.\u20081978;93:62\u201366","DOI":"10.1016\/S0022-3476(78)80601-5"},{"key":"2021120906065024800_R25","doi-asserted-by":"crossref","unstructured":"Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd ed. Stanford, CA: Stanford University Press; 1959","DOI":"10.1097\/00000441-195909000-00030"},{"key":"2021120906065024800_R26","doi-asserted-by":"crossref","unstructured":"Pirazzoli P, Cacciari E, Mandini M, et al. Growth and thyroid function in children treated with growth hormone. J Pediatr.\u20081992;121:210\u2013213","DOI":"10.1016\/S0022-3476(05)81190-4"},{"key":"2021120906065024800_R27","doi-asserted-by":"crossref","unstructured":"Tanner JM, Davies PSW. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr.\u20081985;107:317\u2013329","DOI":"10.1016\/S0022-3476(85)80501-1"},{"key":"2021120906065024800_R28","doi-asserted-by":"crossref","unstructured":"Harder BA, Schaub MC, Eppenberger HM, et al. Influence of fibroblast growth factor (bFGF) and insulin-like growth factor (IGF-I) on cytoskeletal and contractile structures and on atrial natriuretic factor (ANF) expression in adult rat ventricular cardiomyocytes in culture. J Mol Cell Cardiol.\u20081996;28:19\u201331","DOI":"10.1006\/jmcc.1996.0003"},{"key":"2021120906065024800_R29","doi-asserted-by":"crossref","unstructured":"Piwien-Pilipuk G, Huo JS, Schwartz J. Growth hormone signal transduction. J Pediatr Endocrinol Metab.\u20082002;15:771\u2013786","DOI":"10.1515\/JPEM.2002.15.6.771"},{"key":"2021120906065024800_R30","doi-asserted-by":"crossref","unstructured":"von Lewinski D, Voss K, Hulsmann S, et al. Insulin-like growth factor-1 exerts Ca2+-dependent positive inotropic effects in failing human myocardium. Circ Res.\u20082003;92:169\u2013176","DOI":"10.1161\/01.RES.0000051885.70159.12"},{"key":"2021120906065024800_R31","doi-asserted-by":"crossref","unstructured":"Broglio F, Fubini A, Morello M, et al. Activity of GH\/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol.\u20081999;50:417\u2013430","DOI":"10.1046\/j.1365-2265.1999.00696.x"},{"key":"2021120906065024800_R32","doi-asserted-by":"crossref","unstructured":"Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol.\u20082001;38:443\u2013452","DOI":"10.1016\/S0735-1097(01)01385-7"},{"key":"2021120906065024800_R33","doi-asserted-by":"crossref","unstructured":"Broglio F, Benso A, Gottero C, et al. Patients with dilated cardiomyopathy show reduction of the somatotroph responsiveness to GHRH both alone and combined with arginine. Eur J Endocrinol.\u20082000;142:157\u2013163","DOI":"10.1530\/eje.0.1420157"},{"key":"2021120906065024800_R34","doi-asserted-by":"crossref","unstructured":"Giustina A, Volterrani M, Manelli F, et al. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am Heart J.\u20081999;137:1035\u20131043","DOI":"10.1016\/S0002-8703(99)70359-5"},{"key":"2021120906065024800_R35","doi-asserted-by":"crossref","unstructured":"Donath MY, Sutsch G, Yan XW, et al. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab.\u20081998;83:3177\u20133183","DOI":"10.1210\/jc.83.9.3177"},{"key":"2021120906065024800_R36","doi-asserted-by":"crossref","unstructured":"Birnbacher R, Marx M, Wimmer M, et al. A pilot study of growth hormone therapy in dilated cardiomyopathy. Eur J Pediatr.\u20081999;158:340\u2013341","DOI":"10.1007\/s004310051085"},{"key":"2021120906065024800_R37","doi-asserted-by":"crossref","unstructured":"Ikemoto Y, Teraguchi M, Higashino H, et al. Growth hormone treatment of infantile dilated cardiomyopathy. Eur J Pediatr.\u20081999;158:265\u2013266","DOI":"10.1007\/s004310051066"},{"key":"2021120906065024800_R38","doi-asserted-by":"crossref","unstructured":"Daubeney PE, McCaughey ES, Chase C, et al. Cardiac effects of growth hormone in short normal children: results after four years of treatment. Arch Dis Child.\u20081995;72:337\u2013339","DOI":"10.1136\/adc.72.4.337"},{"key":"2021120906065024800_R39","doi-asserted-by":"crossref","unstructured":"Hintz RL, Attie KM, Baptista J, et al. Effect of growth hormone treatment on adult height of children with idiopathic short stature. N Engl J Med.\u20081999;340:502\u2013507","DOI":"10.1056\/NEJM199902183400702"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/4\/e452\/1019835\/zpe0100400e452.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/4\/e452\/1019835\/zpe0100400e452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:17:59Z","timestamp":1639095479000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/4\/e452\/73237\/Recombinant-Human-Growth-Hormone-Treatment-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,1]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,10,1]]},"published-print":{"date-parts":[[2004,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-0072","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2004,10,1]]}}}